Abstracts Archive - Page 229 of 2425 - ACR Meeting Abstracts

Abstract Number: 0578 • ACR Convergence 2023
Prospective Observational Study of Microvascular C5b-9 Deposition in Non-lesional Skin in Systemic Lupus Erythematosus Patients and Its Correlation with Active Lupus Nephritis
Meghan Anderson¹, Cynthia Magro² and H Michael Belmont³, ¹New York University, New York, NY, ²Weill Cornell Medicine, New York, NY, ³NYU School of Medicine, New York, NY
Background/Purpose: Tissue damage in LN is mediated by immune complex activation of the classic complement pathway (PMID 23929771). In a study of LN, renal C5b-9…
Abstract Number: 0584 • ACR Convergence 2023
Targeting Key Components of SLE Pathogenesis with the Multifaceted Immunomodulatory Properties of Cenerimod, a Selective S1P1 Receptor Modulator
Thomas Hoyler¹, Daniel Strasser¹, Ouali Berkani², Peter Cornelisse¹, Mark Murphy¹ and Marianne Martinic¹, ¹Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, ²IDORSIA, Allschwil, Switzerland
Background/Purpose: In SLE, aberrant lymphocyte activation and autoantibody production result in deposition of immune complexes and contribute to tissue damage. Cenerimod, a highly selective S1P1…
Abstract Number: 0560 • ACR Convergence 2023
Genetic Determinants of Lupus Nephritis and Kidney Function in Systemic Lupus Erythematosus
Magdalena Riedl Khursigara¹, Nicholas Gold², Thai-Son Tang³, Daniela Dominguez², Marisa Klein-Gitelman⁴, Dafna Gladman⁵, Daniel Goldman⁶, Elizabeth Harvey², Mariko Ishimori⁷, Caroline Jefferies⁷, Diane L. Kamen⁸, Sylvia Kamphuis⁹, Andrea Knight², Chia-Chi Lee⁷, Deborah Levy², Damien Noone², Karen Onel¹⁰, Christine Peschken¹¹, Michelle Petri⁶, Janet Pope¹², Eleanor Pullenayegum², Earl Silverman¹³, Zahi Touma¹, Murray Urowitz¹⁴, Daniel Wallace⁷, Joan Wither¹⁵ and Linda Hiraki², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Mississauga, ON, Canada, ⁴Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Medical University of South Carolina, Charleston, SC, ⁹Sophia Children’s Hospital, Rotterdam, Netherlands, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²University of Western Ontario, London, ON, Canada, ¹³Silverman, Toronto, ON, Canada, ¹⁴Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ¹⁵University Health Network, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) is one of the most common and severe manifestation of SLE. Risk factors for lupus nephritis and renal function decline are…
Abstract Number: 0599 • ACR Convergence 2023
Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes
Ana Kunzler¹, Meenakshi Jha¹, Masataka Umeda², Rhea Bhargava², Maria Tsokos¹, George Tsokos² and Abhigyan Satyam², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that leads to damage to several tissues and organs. Inflammation of the kidney is one…
Abstract Number: 0597 • ACR Convergence 2023
Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study
Richard A. Furie¹, Kenneth Kalunian², Eric Morand³, Ian Bruce⁴, Susan Manzi⁵, Yoshiya Tanaka⁶, Kevin Withrop⁷, Ihor Hupka⁸, Micki Hultquist⁹, Raj Tummala⁹, Gabriel Abreu¹⁰, Catharina Lindholm¹⁰ and Hussein Al-Mossawi¹¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²University of California San Diego, La Jolla, CA, ³Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁴University of Manchester, Manchester, United Kingdom, ⁵Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ⁸BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland, ⁹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ¹⁰BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹¹BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: SLE is a systemic autoimmune disease requiring long-term treatment. In this placebo-controlled phase 3 TULIP long-term extension (LTE) study,1 the impact of anifrolumab in…
Abstract Number: 0586 • ACR Convergence 2023
Therapeutic Drug Monitoring of Azathioprine and Tacrolimus in SLE Pregnancies: Preliminary Results from the LEGACY Cohort
Reem Farhat¹, Arielle Mendel², Isabelle Malhamé³, Joo Young (Esther) Lee⁴, Luisa Ciofani⁵, Sasha Bernatsky⁶ and Evelyne Vinet², ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵McGill University Health Center, Montreal, QC, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Pregnant SLE women still face an unacceptably high risk of maternal and fetal morbidity, particularly when their disease is active. How to personalize SLE…
Abstract Number: 0577 • ACR Convergence 2023
Analysis of Intracytoplasmic Toll – Like Receptors (TLRs) and MyD88 Expression in B Cell Subsets in Patients with Lupus Nephritis
Michelle Patricia Loeza-Uribe¹, Michelle Nicolle Espinoza-Carranza¹, Yatzil Reyna-Juárez¹, Beatriz Alcalá-Carmona¹, Nancy Raquel Mejía-Domínguez², Guillermo Juárez-Vega², José Luis Maravillas-Montero², Karina Santana-de Anda¹, José Jiram Torres-Ruiz¹ and Diana Gómez-Martín¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Mexico
Background/Purpose: Intrinsic signaling of intracytoplasmic TLRs (7 and 9) and MyD88 in B cells (BC) plays an important role in the development and pathogenesis of…
Abstract Number: 0603 • ACR Convergence 2023
Antiphospholipid Antibodies as Potential Predictors of Disease Severity and Poor Prognosis in Systemic Lupus Erythematosus Associated Thrombocytopeinia
Mehret Birru Talabi¹, Bonnie Bermas², Irene Blanco³, Ashira Blazer⁴, Megan Clowse⁵, Cuoghi Edens⁶, Leslie Pierce⁷, Catherine Wright¹ and Rosalind Ramsey-Goldman³, ¹University of Pittsburgh, Pittsburgh, PA, ²UT Southwestern, Dallas, TX, ³Northwestern University, Chicago, IL, ⁴Hospital for Special Surgery, New York, NY, ⁵Duke University, Chapel Hill, NC, ⁶University of Chicago, Chicago, IL, ⁷University of Pittsburgh, Raleigh, NC
Background/Purpose: Thrombocytopenia (TP) is a common hematologic abnormality in systemic lupus erythematosus (SLE). Severe thrombocytopenia is correlated with disease activity and a worse prognosis of…
Abstract Number: 0492 • ACR Convergence 2023
Axial Spondyloarthritis in Patients with Late-Onset Chronic Low Back Pain (Older Than 45 Years). Axial Spa or Psoriatic Disease with Axial Involvement?
rodrigo garcía salinas¹, Gisel Reyes², Rosario Jaldín Céspedes², Felica Almada² and Sebastián Juan Magri³, ¹Arthritis and Spondyloarthritis Unit, Hospital Italiano de La Plata, National University of La Plata, La Plata, Argentina, ²Hospital Italiano de La Plata, La Plata, Argentina, ³Hospital Italiano La Plata, Melchor Romero, Argentina
Background/Purpose: It is known that patients diagnosed with axSpA do not subsequently meet the classification criteria. The Objectives are: To estimate the diagnostic prevalence of…
Abstract Number: 0598 • ACR Convergence 2023
Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study
Richard Furie¹, Victoria Werth², Eric Milliman³, Kyle Ferber³, Fergal Casey³, Roland Brown³, Denitza Raitcheva³, Jad Zoghbi³, Danielle Graham³, George Kong³, Youmna Lahoud³, Nathalie Franchimont⁴ and Catherine Barbey⁵, ¹Northwell Health, Manhasset, NY, ²University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ³Biogen, Cambridge, MA, ⁴Former employee of Biogen, Cambridge, MA, ⁵Biogen, Baar, Switzerland
Background/Purpose: Litifilimab is a humanized IgG1 mAb targeting BDCA2, a receptor expressed on plasmacytoid dendritic cells (pDCs), that negatively regulates the production of Type I…
Abstract Number: 0609 • ACR Convergence 2023
Mortality After Autologous Hematopoietic Stem Cell Transplant for Autoimmune Disease: Do Scleroderma Patients Fare Worse?
Marina Birck¹, Autumn Neville¹, Jan Storek², Harry Atkins³, Marie Hudson⁴, Ines Colmegna⁵, Jessie R. Lavoie⁶, Jun Gao⁷ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Health Canada, Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Ottawa, ON, Canada, ⁷Health Canada, Centre for Regulatory Excellence, Statistics and Trials, Biologic and Radiopharmaceutical Drugs Directorate, Ottawa, ON, Canada
Background/Purpose: Autologous hematopoietic stem cell transplantation (HSCT) has benefitted some patients with autoimmune disease (AD) but is associated with toxicity and treatment-related mortality. Autologous HSCT…
Abstract Number: 0587 • ACR Convergence 2023
Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data
Daniel Moldaver¹, Seth Anderson², Marguerite Bracher³, Roger A. Levy⁴, Holly A. Quasny⁵, Robert Wood⁶, Rosie Wild⁶, Alexandra Cusmano⁶ and Elke Rottier⁶, ¹GlaxoSmithKline, Value Evidence and Outcomes, Ontario, Canada, ²GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA, ³GlaxoSmithKline, Value Evidence and Outcomes, Stevenage, United Kingdom, ⁴GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁵GlaxoSmithKline, Research & Development, Durham, NC, ⁶Adelphi Real World, Real-World Evidence, Cheshire, United Kingdom
Background/Purpose: The clinical effectiveness of 6-month IV BEL use in SLE has previously been described in a post hoc pooled analysis from six OBSErve cohort…
Abstract Number: 0591 • ACR Convergence 2023
Despite Dramatic Expansion of Approved Biologics in SLE, Unmet Needs Remain
Ryan Rex, Maxine Yarnall and Sawyer May, Spherix Global Insights, Exton, PA
Background/Purpose: This study was conducted to uncover real-world treatment patterns among moderate to severely active systemic lupus erythematosus (SLE) patients in the US.Methods: 1,011 records…
Abstract Number: 0613 • ACR Convergence 2023
Quantification of Skin Hardness of Patients with Systemic Sclerosis Using SOFTGRAM
Hiraku Kokubu¹, Yasuaki Ikuno¹, Kazuyuki Uchiyama¹, Miwa Kato¹, Mayuka Yamamoto¹, Haruki Asada¹, Satona Rikitake¹, Yoshimichi Kobayashi¹, Takahiro Koike¹, Syuji Sugiura¹, Takuma Hayami¹, Kensuke Yoneta¹, Toshifumi Takahashi¹, Bunpei Yamamoto¹, Takeshi Kato¹, Yoshito Kunisaki², Makoto Nakatani², Kohei Okamoto² and Noriki Fujimoto¹, ¹Shiga University of Medical Science, Otsu, Japan, ²ISHIDA MEDICAL CO.,LTD., Kyoto, Japan
Background/Purpose: No quantitative and objective methods for measuring skin hardness have been established. Japanese technology leads the world in the tactile sensor field, and SOFTGRAM…
Abstract Number: 0495 • ACR Convergence 2023
Prevalence of Undiagnosed Inflammatory Bowel Disease in Patients with Spondyloarthritis: EISER Study
Jesus Sanz¹, Zulema Plaza², Jordi Gratacos Masmitja³, Iago Rodríguez -Lago⁴, Elisa Trujillo⁵, Ignacio Marin-Jimenez⁶, Eva Perez-Pampin⁷, Manuel Barreiro de Acosta⁸, Antonio Aznar Esquivel⁹, Marta Carrillo Palau¹⁰, Maria Luz Garcia Vivar¹¹, Maria Carmen Muñoz¹², Lourdes Ladehesa Pineda¹³, Eva Iglesias Flores¹⁴, carolina Merino¹⁵, Yago gonzalez-Lama¹⁶, Marta Arévalo Salaet¹⁷, Xavier calvet¹⁸, Anahy Maria Brandy-Garcia¹⁹, Marta Izquierdo Romero²⁰, SARA MANRIQUE²¹, Raúl Olmedo²², Jose Francisco Garcia Llorente²³, Sandra Pérez²⁴, Inmaculada Ros²⁵, Nuria Rull²⁶, Jose Antonio Pinto Tasende²⁷, Patricia Ucha Abal²⁸, Carlos M González²⁹, Fernando José Rodríguez Martínez³⁰, Soledad Serrano Ladron de Guevara³¹, Marta Domínguez³², Francisco Javier Prado³³, Enrique González-Dávila³⁴ and Ana Gutierrez-Casbas³⁵, ¹Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²Universidad Autónoma de Madrid, Madrid, Spain, ³University Hospital Parc Taulí, Sabadell, Spain, ⁴Gastroenterology department Hospital Galdakao, Galdakao, Spain, ⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁶Public Health System, Madrid, Spain, ⁷Rheumatology Department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ⁸Gastroenterology department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ⁹Rheumatology Department Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Gastroenterology department Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Gastroenterology department Basurto Hospital, Bilbao, Spain, ¹³Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ¹⁴Gastroenterology department Hospital Reina Sofia, Cordoba, Spain, ¹⁵Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, ¹⁶Gastroenterology department Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain, ¹⁷Rheumatology Department University Hospital Parc Taulí, Sabadell, Spain, ¹⁸Gastroenterology department University Hospital Parc Taulí, Sabadell, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Gastroenterology department Hospital Cabueñes, Gijon, Spain, ²¹Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ²²Gastroenterology department Hospital Regional Universitario Málaga, Malaga, Spain, ²³Hospital de Gadakao Usansolo Osakidetza, Bilbao, Spain, ²⁴Gastroenterology department Hospital Galdakao, Galdakao, Spain, ²⁵Rheumatology Department HUSLL, Palma de Mallorca, Spain, ²⁶Gastroenterology department HUSLL, Palma de Mallorca, Spain, ²⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²⁸Gastroenterology department Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ²⁹Rheumatology Department Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ³⁰Rheumatology Department Hospital Universitario General Santa Lucia, Murcia, Spain, ³¹Gastroenterology department Hospital Universitario General Santa Lucia, Murcia, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ³⁴Department of Mathematics, Statistics and Operation Reseach La Laguna University, La Laguna, Spain, ³⁵Gastroenterology department Hospital General Universitario de. Dr. Balmis de Alicante Servicio Digestivo. ISABIAL y CIBERehd, Alicante, Spain
Background/Purpose: EISER is a cross-sectional, multicenter, observational, SER-GETECCU cooperative study involving 13 Spanish hospitals whose main objective was to estimate the prevalence of undiagnosed Inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].